Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
The HEALEY ALS Platform Trial completes enrollment for Regimen E evaluating SLS-005 (Trehalose) by Seelos Therapeutics. The HEALEY ALS Platform Trial completes enrollment for Regimen E evaluating SLS-005 (Trehalose) by Seelos Therapeutics. BOSTON –
The HEALEY ALS Platform Trial is adding a new investigational drug, DNL343, to continue to research new treatments for ALS (Amyotrophic Lateral Sclerosis or Lou Gehrig’s disease).
Healey & AMG Center announces top line results in ALS platform trial with CMN-Au8
Results from the regimen evaluating verdiperstat, an oral myeloperoxidase inhibitor that is thought to reduce neuro-inflammation in adults with amyotrophic lateral sclerosis (ALS).
The Healey & AMG Center for ALS at Mass General and Calico Life Sciences LLC recently signed an agreement to work together to test ABBV-CLS-7262 in the HEALEY ALS Platform Trial.
The Sean. M. Healey & AMG Center for ALS at Massachusetts General Hospital is accepting nominations for the 2022 Drs. Ayeez and Shelena Lalji & Family ALS Endowed Award for Innovative Healing in acknowledgement of the important scientific work being done in ALS.
A team of researchers from the Healey ALS Platform Trial Biomarkers and Outcomes Measures taskforce have released a poster at the European Network to Cure ALS 2022 International Meeting that includes data around remote measurement of baseline speech assessment and vital capacity (VC), a measure of respiratory function.
Merit Cudkowicz, MD, MSc, director of the Sean M. Healey Center for ALS, has been named co-chair of the Optimizing Clinical Research Working Group for the 2022 National Institute of Neurological Disorders and Stroke (NINDS) ALS Strategic Planning Effort.
The Sean M. Healey International Prize for Innovation in ALS Research recognizes an individual or a team of investigators who catalyze exceptional discoveries leading to a transformative advance in therapy development in ALS.
The Gupta Family Endowed Prize for Innovation in ALS Care is an annual global prize to honor ground-breaking new approaches that lead to exceptional care for individuals living with amyotrophic lateral sclerosis (ALS).
Research at Massachusetts General Hospital integrates the full spectrum of "bench to bedside" discovery. Laboratory scientists work collaboratively with clinicians to make discoveries and turn them into treatments, diagnostics and devices that improve our quality of life.